Affymax gets $10M milestone, PDUFA date on anemia drug

Affymax ($AFFY) is pocketing a $10 million milestone from Takeda on the news that the FDA has accepted the NDA for the anemia treatment peginesatide, a drug formerly known as Hematide. Earlier today Affymax also noted that the FDA had assigned a March 27 action date for the drug. If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent available for anemia associated with CKD patients on dialysis in the United States. Release | Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.